Progressive Ataxia and Cognitive Impairment Associated With SEZ6L2: Serum Neurofilament Light Chain as a Biomarker of Disease Activity
Brain and Behavior · 2026-11 · 16 (11)
DOI: 10.1002/brb3.71900 ↗Kurz gefasst
Fallbericht in der Zeitschrift Brain and Behavior, online erschienen am 10.11.2026. Verfasst von Carlo Fazio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Neurofilament Proteins, Cognitive Dysfunction, Encephalitis, Cerebellar Ataxia. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health "Ricerca Corrente 2025-2027".
Abstract (Originalsprache)
Introduction
Autoimmune encephalitis (AE) associated with SEZ6L2 antibodies is a rare neurological disorder characterized by subacute onset of cerebellar ataxia, cognitive dysfunction, and extrapyramidal features. Few cases have been reported, and data on long‐term course and treatment response remain limited. Case Presentation A 64‐year‐old woman developed progressive cerebellar ataxia, cognitive decline, and psychiatric symptoms starting insidiously after SARS‐CoV‐2 pneumonia in September 2022. Magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis almost 1 year after onset were unremarkable. Due to progressive symptoms, she was admitted to our department in December 2024. Examination showed severe truncal and gait ataxia, memory impairment, and prominent frontal‐executive dysfunction. Brain MRI demonstrated bilateral hippocampal T2 hyperintensity with severe medial temporal lobe and cerebellar atrophy. Neuronal antibody testing with a tissue‐based assay (TBA) optimized for surface antigens showed strong neuropilar hippocampal and cerebellar staining in serum and CSF. A specific live cell‐based assay (CBA) confirmed that the reactivity could be attributed to SEZ6L2 antibodies. Plasmapheresis and high‐dose corticosteroids resulted in stabilization of gait impairment and mild cognitive improvement. Longitudinal plasma neurofilament light chain (NFL) monitoring showed initially high levels (85.12 pg/mL), followed by a drastic reduction some months after immunotherapy.
Conclusions
AE can mimic neurodegenerative processes, and SEZ6L2 antibody testing should be considered in patients with progressive ataxia and limbic involvement, even when no additional clues point towards an autoimmune etiology. Notably, the condition manifested a partial response to immunotherapy, supported by NFL reduction. This suggests that NFL might represent a useful biomarker to monitor disease activity in these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
- IRCCS Mondino Foundation, Pavia, Italy.
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
- Neuroimmunology Research Section, IRCCS Mondino Foundation, Pavia, Italy.
Förderung
- Italian Ministry of Health "Ricerca Corrente 2025-2027"
Zitieren
APA
Fazio, C., Regalbuto, S., Arceri, S., Comolli, D., Calculli, A., Trobbiani, G., Battaglia, G., Zuliani, F., Gastaldi, M., & Pisani, A. (2026). Progressive Ataxia and Cognitive Impairment Associated With SEZ6L2: Serum Neurofilament Light Chain as a Biomarker of Disease Activity. Brain and Behavior, 16(11). https://doi.org/10.1002/brb3.71900
Vancouver
Fazio C, Regalbuto S, Arceri S, Comolli D, Calculli A, Trobbiani G, et al. Progressive Ataxia and Cognitive Impairment Associated With SEZ6L2: Serum Neurofilament Light Chain as a Biomarker of Disease Activity. Brain and Behavior. 2026;16(11). doi:10.1002/brb3.71900
BibTeX
@article{Fazio2026,
author = {Fazio, Carlo and Regalbuto, Simone and Arceri, Sebastiano and Comolli, Davide and Calculli, Alessandra and Trobbiani, Giulio and Battaglia, Giuseppe and Zuliani, Federica and Gastaldi, Matteo and Pisani, Antonio},
title = {Progressive Ataxia and Cognitive Impairment Associated With SEZ6L2: Serum Neurofilament Light Chain as a Biomarker of Disease Activity},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/brb3.71900}
}
EUVIMED